title: [New prospects for the treatment of systemic lupus erythematosus].
abstract: The systemic lupus erythematosus is a significant therapeutic challenge: Multiorgan involvement and a variable disease course, characterized by clinical exacerbations and remissions, make difficult to predict the outcome. Few products have been specifically developed for this affection, and most accepted therapies have not been tested in randomized controlled trials of systemic lupus erythematosus. A variety of biological agents under investigation as potential treatments for systemic lupus erythematosus are designed to interfere with specific immunologic responses, hopefully avoiding generalized immunosuppression. Agents, which interfere with T cell-B cell collaboration, such as CTLA-4-Ig and anti-CD154 ligand monoclonal antibodies, may result in long-term therapeutic benefit. Products designed to decrease production of anti-dsDNA antibodies or inhibit complement activation, may prevent immune complex deposition and ameliorate organ-specific manifestations, such as renal disease. More aggressive interventions include gene therapy and stem cell transplantation.
authors.affiliation: Alergólogo e inmunólogo clínico, adscrito al departamento de medicina interna del Hospital de Especialidades del Centro Médico Nacional La Raza, IMSS, México, DF.
authors.forename: Felipe
authors.initials: F
authors.lastname: Iniestra Flores
authors.forename: Modesto
authors.initials: M
authors.lastname: Orea Solano
mesh_terms: D000069594:Abatacept; D000818:Animals; D000974:Antibodies, Antinuclear / Q000096:biosynthesis / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D023201:CD40 Ligand / Q000276:immunology; D003167:Complement Activation / Q000187:drug effects; D004247:DNA / Q000276:immunology; D004353:Drug Evaluation, Preclinical; D005544:Forecasting; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D016753:Interleukin-10 / Q000037:antagonists & inhibitors / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*; D008181:Lupus Nephritis / Q000188:drug therapy; D008211:Lymphocyte Cooperation; D051379:Mice; D008814:Mice, Inbred NZB; D009841:Oligonucleotides / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics
chemical_list: D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D009841:Oligonucleotides; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D023201:CD40 Ligand; D000069594:Abatacept; D004247:DNA; C094104:abetimus